Wikipedia

Lola Eniola-Adefeso

Omolola (Lola) Eniola-Adefeso is a Nigerian-American chemical engineer and incoming Dean of the College of Engineering at the University of Illinois Chicago.[1]

Lola Eniola-Adefeso
Eniola-Adefeso in NIGMS Findings Magazine, 2009
Born
Maryland, USA
Alma materUniversity of Maryland, Baltimore County
University of Pennsylvania
Scientific career
InstitutionsUniversity of Illinois Chicago

University of Michigan

Baylor College of Medicine
Websitehttps://che.engin.umich.edu/people/lola-eniola-adefeso/

She is currently the Vennema Endowed Professor of Chemical Engineering, the Associate Dean for Graduate and Professional Education, and University Diversity and Social Transformation Professor of Chemical Engineering, Biomedical Engineering, and Macromolecular Science and Engineering at the University of Michigan College of Engineering.[2]

Eniola-Adefeso is also a co-founder and chief scientific officer of Asalyxa Bio. Her research looks to design biocompatible functional particles for targeted drug delivery.

Education

edit

Eniola-Adefeso moved to Maryland from Nigeria at the age of 16.[3] She was going to attend medical school but became interested in chemical engineering.[4] Eniola-Adefeso studied Chemical and Biomolecular Engineering at University of Maryland, Baltimore County, graduating in 1999.[5] She moved to University of Pennsylvania for her postgraduate studies, graduating in 2004.[5][6]

Career

edit

Scientific impact

edit
 
Eniola-Adefeso in NIGMS Findings Magazine, 2009.

After completing her graduate studies, Eniola-Adefeso worked in the Baylor College of Medicine as a National Institutes of Health postdoctoral fellow.[7][8] Eniola-Adefeso joined University of Michigan in 2006.[9] In 2013, she was named a Miller Faculty Scholar at the University of Michigan and now also serves as the associate dean for graduate and professional education in the college of engineering.[10][11][12][13] She is interested in the interactions between blood leukocytes and endothelial cells in vessel lumen lining, and how they change during inflammation response.[8][14] After losing her father to heart disease, Eniola-Adefeso began to research new treatments for it.[15][16]

Eniola-Adefeso’s research has focused on leveraging hemodynamics to design novel, vascular-targeted particle therapies. Repeatedly challenging the status quo, she has published a multitude of game-changing “firsts” in the field. Publications from her lab were the first to demonstrate that nanoparticles' size, shape, and density – acting as “vascular-targeting drug carriers (VTCs)”- matter in their ability to reach and bind the blood vessel wall. This bold body of work has been instrumental in “redefining the problem” of advancing the development of novel controlled delivery solutions to vascular diseases and is catalyzing novel solutions. Her lab’s systematic use of ex vivo models of human microvessels and blood flows, followed closely with in vivo assays in mice, sensitized the biomedical engineering field to recognizing “blood as a tissue” with distinct features across species.

Her lab has since leveraged its models to reveal new information about neutrophils (PMNs) and their interactions with VTCs. They provided the first evidence of circulating PMNs rapidly binding and phagocytosing particles within minutes.[17] This landmark observation paved the way for her lab’s interest in particle-based immunomodulation of PMNs in acute and chronic inflammatory conditions.

Eniola-Adefeso always aims to leverage fundamental science discovery in her lab toward clinical applications. In this vein, she demonstrated in a Science Advances publication from 2020 that human neutrophils prefer to phagocytose (i.e., eat) rod-shaped particles, which is counter to the widely accepted notion in the literature – primarily based on work with mouse blood and cell lines – that blood phagocytes do not effectively eat rods.[18] This revelation offers a novel approach to targeting neutrophils in numerous diseases.

Her critical discovery, coupled with an innovative polymer, has led to the recent formation of a startup company, Asalyxa Bio, where Eniola-Adefeso holds the chief scientific officer position.[19] Since its incorporation in July, she has led the company to raise funds for a first-in-human clinical trial toward developing this technology to treat Acute Respiratory Distress Syndrome (ARDS).

Eniola-Adefeso is a Fellow of the American Institute for Medical and Biological Engineers (AIMBE) and Biomedical Engineering Society (BMES). She serves as a deputy editor for Science Advances, on the board of directors for AICHE and AIMBE, and as a member of the external advisory board for the biomedical engineering department at the University of Florida and Boston University.

Diversity, equity, and inclusion work

edit

Eniola-Adefeso is a champion for women and underrepresented minority students within University of Michigan.[20] She has established a mentoring scheme and served as graduate chair, recruiting the most diverse cohort of students in the department's history.[21][20] She encouraged undergraduate students to develop experiments for K-12 teachers to use in their classrooms.[20] Eniola-Adefeso has been involved in the College of Engineering NextProf program, which brings women and minority students to campus to experience academic life.[20] In 2018, along with Professor Chinedum Okwudire, she co-established the NextProf Pathfinder Workshop,[22] a future-faculty program specifically aimed at first- and second-year PhD students, rather than final year PhD students and postdoctoral fellows, as is typical in many other institutions. The goal of the NextProf Pathfinder Workshop is to equip the attendees – mostly women and students from underrepresented groups – with the knowledge and skills needed to develop strong CVs, early in their PhD process, to make them competitive for faculty positions. The NextProf Pathfinder program has now expanded to include the University of California, San Diego and the Georgia Institute of Technology.

In 2021, Eniola-Adefeso and BME colleagues from many US institutions called out racial funding disparity by the National Institutes of Health garnering support for these larger institutional DEI changes from both academic and non-academic communities.[23] The paper and the national advocacy effort led by Eniola-Adefeso led the NIH Director to publicly apologize for ‘structural racism,’ in NIH funding and pledges actions”.[24]

Honors and fellowships

edit

Select publications

edit
  • Roy van der Meel; Marcel H A M Fens; Pieter Vader; Wouter W van Solinge; Omolola Eniola-Adefeso; Raymond M Schiffelers (2 August 2014). "Extracellular vesicles as drug delivery systems: lessons from the liposome field". Journal of Controlled Release. 195: 72–85. doi:10.1016/J.JCONREL.2014.07.049. ISSN 0168-3659. PMID 25094032. Wikidata Q38237168.
  • Phapanin Charoenphol; Ryan B Huang; Omolola Eniola-Adefeso (2 December 2009). "Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carriers". Biomaterials. 31 (6): 1392–1402. doi:10.1016/J.BIOMATERIALS.2009.11.007. ISSN 0142-9612. PMID 19954839. Wikidata Q47582525.
  • Phapanin Charoenphol; Supriya Mocherla; Diane Bouis; Katawut Namdee; David J Pinsky; Omolola Eniola-Adefeso (22 April 2011). "Targeting therapeutics to the vascular wall in atherosclerosis--carrier size matters". Atherosclerosis. 217 (2): 364–370. doi:10.1016/J.ATHEROSCLEROSIS.2011.04.016. ISSN 0021-9150. PMID 21601207. Wikidata Q38334991.

References

edit
  1. ^ "Lola Eniola-Adefeso named College of Engineering dean | UIC today". today.uic.edu. Retrieved 2024-07-16.
  2. ^ "Lola Eniola-Adefeso". Chemical Engineering. Retrieved 2024-07-16.
  3. ^ "Highways to Healing – Omolola Eniola-Adefeso '99, ChemEng". 2 September 2011.
  4. ^ a b "Meyerhoff Scholar – News and Stories for UMBC Alumni". umbcalumni.wordpress.com. Retrieved 2018-05-09.
  5. ^ a b "Lola Eniola-Adefeso – Chemical Engineering". che.engin.umich.edu. Retrieved 2018-05-09.
  6. ^ "CBE – Lola Eniola-Adefeso, ChE PhD'04 Elected to the College of Fellows at AIMBE". www.cbe.seas.upenn.edu. Retrieved 2018-05-09.
  7. ^ "Diversity Program Alumni Updates: Omolola Eniola-Adefeso, Ph.D. – National Institute of General Medical Sciences". www.nigms.nih.gov. Retrieved 2018-05-09.
  8. ^ a b "Omolola Eniola-Adefeso, PhD". Michigan Center for Integrative Research in Critical Care. Retrieved 2018-05-09.
  9. ^ a b "Eniola Adefeso receives University honor and promotion to professor | Michigan Engineering". Michigan Engineering. Retrieved 2018-05-09.
  10. ^ "Lola Eniola-Adefeso – Chemical Engineering". che.engin.umich.edu. Retrieved 2021-02-26.
  11. ^ a b "Lola Eniola-Adefeso elected fellow of AIMBE | Michigan Engineering". Michigan Engineering. Retrieved 2018-05-09.
  12. ^ "Alumni Promotions and Awards" (PDF). University of Penn. Retrieved 2018-05-09.
  13. ^ "Lola Eniola-Adefeso promoted to associate professor | Michigan Engineering". Michigan Engineering. Retrieved 2018-05-09.
  14. ^ "UMBC Meyerhoff Scholars Program". www.umbc.edu. Retrieved 2018-05-09.
  15. ^ NIGMS (2010-09-10), NIGMS Grantee Dr. Lola Eniola-Adefeso on Developing New Heart Disease Drugs, retrieved 2018-05-09
  16. ^ "Special Delivery – September 2009 – Findings – Science Publication – National Institute of General Medical Sciences". publications.nigms.nih.gov. Retrieved 2018-05-09.
  17. ^ Fromen, Catherine A.; Kelley, William J.; Fish, Margaret B.; Adili, Reheman; Noble, Jeffery; Hoenerhoff, Mark J.; Holinstat, Michael; Eniola-Adefeso, Omolola (November 28, 2017). "Neutrophil–Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation". ACS Nano. 11 (11): 10797–10807. doi:10.1021/acsnano.7b03190. PMC 5709153. PMID 29028303.
  18. ^ Safari, Hanieh; Kelley, William J.; Saito, Eiji; Kaczorowski, Nicholas; Carethers, Lauren; Shea, Lonnie D.; Eniola-Adefeso, Omolola (2020-06-12). "Neutrophils preferentially phagocytose elongated particles—An opportunity for selective targeting in acute inflammatory diseases". Science Advances. 6 (24): eaba1474. doi:10.1126/sciadv.aba1474. ISSN 2375-2548. PMC 7286665. PMID 32577517.
  19. ^ "Biotech | Orange Grove Bio Team". Asalyxa. Retrieved 2021-02-27.
  20. ^ a b c d e "Eniola-Adefeso wins College of Engineering award | Michigan Engineering". Michigan Engineering. Retrieved 2018-05-09.
  21. ^ "Mentoring Moment with Dr. Lola Eniola-Adefeso (UMBC Alum)". myUMBC. Retrieved 2018-05-09.
  22. ^ "NextProf Pathfinder". nextprofpathfinder.engin.umich.edu. Retrieved 2023-10-06.
  23. ^ Stevens, Kelly R.; Masters, Kristyn S.; Imoukhuede, P.I.; Haynes, Karmella A.; Setton, Lori A.; Cosgriff-Hernandez, Elizabeth; Lediju Bell, Muyinatu A.; Rangamani, Padmini; Sakiyama-Elbert, Shelly E.; Finley, Stacey D.; Willits, Rebecca K.; Koppes, Abigail N.; Chesler, Naomi C.; Christman, Karen L.; Allen, Josephine B.; Wong, Joyce Y.; El-Samad, Hana; Desai, Tejal A.; Eniola-Adefeso, Omolola (2021-02-04). "Fund Black scientists". Cell. 184 (3): 561–565. doi:10.1016/j.cell.2021.01.011. ISSN 0092-8674. PMID 33503447.
  24. ^ "NIH director apologizes for 'structural racism,' pledges actions". www.science.org.
  25. ^ MLK Visiting Professorship, MIT
  26. ^ "Biomedical Engineering Society".
  27. ^ "BMES Mid-Career Award".
  28. ^ Scholars, The Community of. "1,000 inspiring Black scientists in America". crosstalk.cell.com.
  29. ^ "Eniola-Adefeso Lab Group Website". cheresearch.engin.umich.edu.
  30. ^ "Office of the Provost | Harold R. Johnson Diversity Service Award". www.provost.umich.edu. Retrieved 2018-05-09.
  31. ^ "NSF Award Search: Award#1054352 – CAREER: Defining the interplay between hemodynamics and shape/size in particle localization to the vascular wall – an integrated in vitro and in vivo study". www.nsf.gov. Retrieved 2018-05-09.
  32. ^ "Lola Eniola-Adefeso". www.aiche.org. 29 August 2017. Retrieved 2018-05-09.
  33. ^ a b c "Eniola Research Group – Cell Adhesion & Drug Delivery". cheresearch.engin.umich.edu. Retrieved 2018-05-09.
Retrieved from "https://en.wiki.x.io/w/index.php?title=Lola_Eniola-Adefeso&oldid=1257826068"